Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Liabilities from Discontinued Operations: 2023

Historic Liabilities from Discontinued Operations for Seres Therapeutics (MCRB) over the last 1 years, with Dec 2023 value amounting to $109.4 million.

  • Seres Therapeutics' Liabilities from Discontinued Operations was N/A to $109.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $109.4 million, marking a year-over-year change of. This contributed to the annual value of $109.4 million for FY2023, which is N/A change from last year.
  • Per Seres Therapeutics' latest filing, its Liabilities from Discontinued Operations stood at $109.4 million for FY2023.
  • Seres Therapeutics' 5-year Liabilities from Discontinued Operations high stood at $109.4 million for FY2023, and its period low was $109.4 million during FY2023.
  • Over the past 1 years, Seres Therapeutics' median Liabilities from Discontinued Operations value was $109.4 million (recorded in 2023), while the average stood at $109.4 million.